|Table of Contents|

Research on the role of CD38 in tumor microenvironment and the progress in the treatment of solid tumors

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 03
Page:
553-558
Research Field:
Publishing date:

Info

Title:
Research on the role of CD38 in tumor microenvironment and the progress in the treatment of solid tumors
Author(s):
LU Xinyi1; CHEN Daozhen1; 2
1.Wuxi Maternal and Child Health Hospital Affiliated to Nanjing Medical University,Jiangsu Wuxi 214002,China;2.Haidong Second People's Hospital,Qinghai Haidong 810904,China.
Keywords:
CD38; tumor microenvironment; tumor therapy
PACS:
R730.2
DOI:
10.3969/j.issn.1672-4992.2024.03.030
Abstract:
Tumor microenvironment includes myeloid cells,lymphocytes,fibroblasts and mesenchymal stem cells.When the microenvironment homeostasis is disrupted,the interaction between various components leads to the occurrence,growth and metastasis of tumors.CD38,a transmembrane glycoprotein,expresses unbalanced in many solid tumors.It helps to create an immunosuppressive microenvironment,thus promoting tumor growth and inhibiting immune cell activity.Therefore,the strategy of regulating the expression of CD38 in tumor microenvironment to improve anti-tumor effect has been proposed.The use of tumor antibody targeted drugs has promoted the progress of medicine.Further research will be focus on the function of CD38 and its mechanism of action in tumorigenesis and development,providing a basis for CD38 to become a new target for immunotherapy of solid tumors.

References:

［1］ALESSIO M,ROGGERO S,FUNARO A,et al.CD38 molecule:structural and biochemical analysis on human T lymphocytes,thymocytes,and plasma cells ［J］.J Immunol,1990,145(3):878-884.
［2］ASTIGIANO C,BENZI A,LAUGIERI ME.Paracrine ADP ribosyl cyclase-mediated regulation of biological processes［J］.Cells,2022,11(17):2637.
［3］FUNARO A,SPAGNOLI GC,AUSIELLO CM,et al.Involvement of the multilineage CD38 molecule in a unique pathway of cell activation and proliferation ［J］.J Immunol,1990,145(8):2390-2396.
［4］GUERREIRO S,PRIVAT AL,BRESSAC L,et al.CD38 in neurodegeneration and neuroinflammation ［J］.Cells,2020,9(2):471.
［5］GUEDESAG,DILEEPAN M,JUDE JA,et al.Role of CD38/cADPR signaling in obstructive pulmonary diseases ［J］.Curr Opin Pharmacol,2020,51:29-33.
［6］ZHANG M,YANG J,ZHOU J,et al.Prognostic values of CD38(+)CD101(+)PD1(+)CD8(+) T cells in pancreaticcv cancer ［J］.Immunol Invest,2019,48(5):466-479.
［7］DEAGLIO S,MEHTA K,MALAVASI F.Human CD38:a (r)evolutionary story of enzymes and receptors ［J］.Leuk Res,2001,25(1):1-12.
［8］WO YJ,GAN ASP,LIM X,et al.The roles of CD38 and CD157 in the solid tumor microenvironment and cancer immunotherapy ［J］.Cells,2019,9(1):26.
［9］HORENSTEIN AL,CHILLEMI A,ZACCARELLO G,et al.A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes ［J］.Oncoimmunology,2013,2(9):e26246.
［10］KONEN JM,FRADETTE JJ,GIBBONS DL.The good,the bad and the unknown of CD38 in the metabolic microenvironment and immune cell functionality of solid tumors［J］.Cells,2019,9(1):52.
［11］CALIGIURI G.Mechanotransduction,immunoregulation,and metabolic functions of CD31 in cardiovascular pathophysiology ［J］.Cardiovasc Res,2019,115(9):1425-1434.
［12］DEAGLIO S,MORRA M,MALLONE R,et al.Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31,an Ig superfamily member ［J］.J Immunol,1998,160(1):395-402.
［13］MALAVASI F,DEAGLIO S,FUNARO A,et al.Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology ［J］.Physiol Rev,2008,88(3):841-886.
［14］ZENG F,ZHANG J,JIN X,et al.Effect of CD38 on B-cell function and its role in the diagnosis and treatment of B-cell-related diseases ［J］.J Cell Physiol,2022,237(7):2796-2807.
［15］NABAR NR,HEIJJER CN,SHI CS,et al.LRRK2 is required for CD38-mediated NAADP-Ca(2+) signaling and the downstream activation of TFEB (transcription factor EB) in immune cells ［J］.Autophagy,2022,18(1):204-222.
［16］VAUPELP,MULTHOFF G.Accomplices of the hypoxic tumor microenvironment compromising antitumor immunity:adenosine,lactate,acidosis,vascular endothelial growth factor,potassium ions,and phosphatidylserine［J］.Front Immunol,2017,8:1887.
［17］DWIVEDI S,RENDON-HUERTA EP,ORTIZ-NAVARRETE V,et al.CD38 and regulation of the immune response cells in cancer ［J］.J Oncol,2021,2021:6630295.
［18］MORELLO S,PINTO A,BLANDIZZI C,et al.Myeloid cells in the tumor microenvironment:role of adenosine ［J］.Oncoimmunology,2016,5(3):e1108515.
［19］ARAB S,HADJATI J.Adenosine blockage in tumor microenvironment and improvement of cancer immunotherapy ［J］.Immune Netw,2019,19(4):e23.
［20］HORENSTEIN AL,QUARONA V,TOSCANI D,et al.Adenosine generated in the bone marrow niche through a cd38-mediated pathway correlates with progression of human myeloma［J］.Mol Med,2016,22:694-704.
［21］HALPIN-VESZELEIOVA K,HATFIELD SM.Oxygenation and A2AR blockade to eliminate hypoxia/HIF-1alpha-adenosinergic immunosuppressive axis and improve cancer immunotherapy ［J］.Curr Opin Pharmacol,2020,53:84-90. ［22］FAVIA A,PAFUMI I,DESIDERI M,et al.NAADP-dependent Ca(2+) signaling controls melanoma progression, metastatic dissemination and neoangiogenesis［J］.Sci Rep,2016,6:18925.
［23］GALIONE A.NAADP receptors ［J］.Cold Spring Harb Perspect Biol,2019,11(11):a035071.
［24］VAN DE DONK NWCJ,PAWLYN C,YONG KL.Multiple myeloma ［J］.Lancet,2021,397(10272):410-427.
［25］NEUMEISTER P,SCHULZ E,PANSY K,et al.Targeting the microenvironment for treating multiple myeloma ［J］.Int J Mol Sci,2022,23(14):7627.
［26］SHALLIS RM,TERRY CM,LIM SH.The multi-faceted potential of CD38 antibody targeting in multiple myeloma ［J］.Cancer Immunol Immunother,2017,66(6):697-703.
［27］SALTARELLA I,DESANTIS V,MELACCIO A,et al.Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma ［J］.Cells,2020,9(1):167.
［28］YI M,NIU M,XU L,et al.Regulation of PD-L1 expression in the tumor microenvironment ［J］.J Hematol Oncol,2021,14(1):10.
［29］NG HHM,LEE RY,GOH S,et al.Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma ［J］.J Immunother Cancer,2020,8(2):e000987.
［30］CHEN L,DIAO L,YANG Y,et al.CD38-Mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade ［J］.Cancer Discov,2018,8(9):1156-1175.
［31］COSTA F,MARCHICA V,STORTI P,et al.PD-L1/PD-1 axis in multiple myeloma microenvironment and a possible link with CD38-mediated immune-suppression ［J］.Cancers(Basel),2021,13(2):164.
［32］FRAMPTON JE.Isatuximab:a review of its use in multiple myeloma ［J］.Target Oncol,2021,16(5):675-686.
［33］NAHI H,CHROBOK M,GRAN C.Infectious complications and NK cell depletion following daratumumab treatment of multiple myeloma ［J］.PLoS One,2019,14(2):e0211927.
［34］OGIYA D,LIU J,OHGUCHI H,et al.The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment:therapeutic implications ［J］.Blood,2020,136(20):2334-2345.
［35］MEI H,LI C,JIANG H,et al.A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma ［J］.J Hematol Oncol,2021,14(1):161.
［36］TANG Y,YIN H,ZHAO X,et al.High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma ［J］.J Exp Clin Cancer Res,2022,41(1):2.
［37］CUI Q,QIAN C,XU N,et al.CD38-directed CAR-T cell therapy:a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation ［J］.J Hematol Oncol,2021,14(1):82.
［38］SANDHU S,MOORE CM,CHIONG E,et al.Prostate cancer ［J］.Lancet,2021,398(10305):1075-1090.
［39］GUO C,CRESPO M,GUREL B,et al.CD38 in advanced prostate cancers ［J］.Eur Urol,2021,79(6):736-746.
［40］CHMIELEWSKI JP,BOWLBY SC,WHEELER FB,et al.CD38 inhibits prostate cancer metabolism and proliferation by reducing cellular NAD(+) pools［J］.Mol Cancer Res,2018,16(11):1687-1700.
［41］CHATTERJEE S,CHAKRABORTY P,MEHROTRA S.CD38- NAD(+)-sirt1 axis in T cell immunotherapy ［J］.Aging (Albany NY),2019,11(20):8743-8744.
［42］CHATTERJEE S,DAENTHANASANMAK A,CHAKRABORTY P,et al.CD38-NAD(+)axis regulates immunotherapeutic anti-tumor T cell response ［J］.Cell Metab,2018,27(1):85-100.
［43］ZUCALI PA,LIN CC.Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies:results from a phase I/II open-label,multicenter study ［J］.J Immunother Cancer,2022,10(1):e003697.
［44］CHANDRAN E,MEININGER L,KARZAI F,et al.Signaling new therapeutic opportunities:cytokines in prostate cancer ［J］.Expert Opin Biol Ther,2022,22(10):1233-1243.
［45］ATTADEMO L,TUNINETTI V,PISANO C,et al.Immunotherapy in cervix cancer ［J］.Cancer Treat Rev,2020,90:102088.
［46］SHI X,DENG Z,WANG S,et al.Increased HSF1 promotes infiltration and metastasis in cervical cancer via enhancing MTDH-VEGF-C expression ［J］.Onco Targets Ther,2021,14:1305-1315.
［47］LIAO S,XIAO S,CHEN H,et al.CD38 enhances the proliferation and inhibits the apoptosis of cervical cancer cells by affecting the mitochondria functions ［J］.Mol Carcinog,2017,56(10):2245-2257.
［48］LIAO S,LIANG L,YUE C,et al.CD38 is involved in cell energy metabolism via activating the PI3K/AKT/mTOR signaling pathway in cervical cancer cells ［J］.Int J Oncol,2020,57(1):338-354.
［49］LI H,PREVER L,HIRSCH E,et al.Targeting PI3K/AKT/mTOR signaling pathway in breast cancer ［J］.Cancers (Basel),2021,13(14):3517.
［50］SUN D,ZHANG M,WEI M,et al.Ox-LDL-mediated ILF3 overexpression in gastric cancer progression by activating the PI3K/AKT/mTOR signaling pathway ［J］.Aging (Albany NY),2022,14(9):3887-3909.
［51］LI X,QU LX,REN YM,et al.Case report and literature review on severe bullous skin reaction induced by anti-PD-1 immunotherapy in a cervical cancer patient ［J］.Front Pharmacol,2021,12:707967.
［52］DORTA-ESTREMERA S,HEGDE VL,SLAY RB,et al.Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV(+) oral cancer ［J］.J Immunother Cancer,2019,7(1):252.

Memo

Memo:
青海省自然科学基金项目（编号：2022-ZJ-912）
Last Update: 2023-12-29